Ellin Berman, MD
Leukemia Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Leukemia
- Blood, bone marrow, and hematologic cancers and conditions
- Myelodysplastic syndrome (MDS)
My Specialties
- Clinical trials
Meet Leukemia Expert Ellin Berman
Video DetailsAbout Me
- Attending Physician
I am a board-certified medical oncologist and hematologist with a clinical and research focus on new drug development in acute and chronic leukemias, including acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). As a member of the multidisciplinary Leukemia Disease Management Team, I work closely with the many individuals who make up the clinical and research programs here.
Read more
Along with other members of the Leukemia Service, I am involved in clinical trials of new drugs that hopefully will lead to new treatment approaches for these diseases. I have also worked closely with the Food and Drug Administration in this regard, and for the last 20 years have helped review new drug applications for the treatment of leukemia.
My current research focuses on understanding how the cells within the bone marrow interact with leukemia cells. We have recently shown that the drug imatinib — one of a relatively new class of agents called tyrosine kinase inhibitors that inhibit growth of CML cells — can also inhibit other cells within the bone marrow that affect growth of bone. In conjunction with researchers here and at other institutions, we have begun to examine how cells within the bone marrow communicate with each other.
I am also interested in why some patients with CML progress despite treatment with imatinib. In collaboration with colleagues here, we have begun to study abnormalities of the CML protein that may explain why imatinib is ineffective in some patients.
As a member of the National Comprehensive Cancer Network, I am also involved in defining the standard of care for patients with CML. I am a member of Memorial Sloan Kettering’s Institutional Review Board (IRB), the committee that approves, monitors, and reviews research studies at the Center. I am an Associate Editor for the journal Leukemia Research, and review articles for a number of other journals including Blood. the Journal of Clinical Oncology, Cancer Research, The Lancet, and the New England Journal of Medicine.
A leukemia specialist is a doctor with special training in diagnosing and treating leukemia.
Conditions I Treat
- Leukemia
- Blood, bone marrow, and hematologic cancers and conditions
- Myelodysplastic syndrome (MDS)
- Acute lymphocytic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Acute promyelocytic leukemia (APL)
- Chronic myeloid leukemia (CML)
- Chronic lymphocytic leukemia (CLL)
- Myeloproliferative neoplasms (MPN)/Myeloproliferative disorders
- Hairy cell leukemia (HCL)
- Systemic mastocytosis
My Specialties
- Clinical trials
Education
- MD, Harvard Medical School
Residencies
- Internal Medicine - Boston University Medical Center
Awards and Honors
- Castle Connolly: Exceptional Women in Medicine (2024)
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Exceptional Women in Medicine Award, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2017-2018)
Fellowships
- Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Hematology
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Berman sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Berman
- A Phase 1 Study of TERN-701 in People With Chronic Myeloid Leukemia
- A Phase 2 Study of Asciminib as Initial Therapy for Chronic Myeloid Leukemia in Chronic Phase
- Stopping Treatment a Second Time After One Year Combination Treatment with Asciminib and Imatinib for Chronic Myeloid Leukemia that Came Back After Previously Trying to Stop Imatinib
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Berman’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Ellin Berman discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].